| Item type |
琉球大学リポジトリ登録用アイテムタイプ(1) |
| 公開日 |
2024-12-01 |
| タイトル |
|
|
タイトル |
Effectiveness of Surveillance by Echocardiography for Cancer Therapeutics-Related Cardiac Dysfunction of Patients with Breast Cancer |
|
言語 |
en |
| 作成者 |
Okushi, Yuichiro
Saijo, Yoshihito
Yamada, Hirotsugu
Toba, Hiroaki
Zheng, Robert
Seno, Hiromitsu
Takahashi, Tomonori
Ise, Takayuki
Yamaguchi, Koji
Yagi, Shusuke
Soeki, Takeshi
Wakatsuki, Tetsuzo
Sata, Masataka
Kusunose, Kenya
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
言語 |
en |
|
権利情報Resource |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja |
|
権利情報 |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) license |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Heart failure |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cardio oncology |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cardiotoxic drugs |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Echocardiography surveillance |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Cancer therapeutics-related cardiac dysfunction (CTRCD) affect the prognosis of patients with breast cancer. Echocardiographic surveillance of patients treated with anti-human epidermal growth factor receptor type 2 (HER2) antibodies has been recommended, but few reports have provided evidence on patients with breast cancer only. We aimed to evaluate the effectiveness of echocardiographic surveillance for breast cancer patients. Methods: We identified 250 patients with breast cancer who were treated with anti-HER2 antibodies from July 2007 to September 2021. We divided 48 patients with echocardiographic surveillance every 3 months into the surveillance group and 202 patients without echocardiographic surveillance into the non-surveillance group. In the surveillance group, patients with a considerable reduction in global longitudinal strain of 15% were considered for the initiation of cardioprotective drugs. The composite outcome of CTRCD and acute heart failure was the study endpoint. Results: The mean age was 59 ± 12 years. During the follow-up period of 15 months (12- 17 months), 12 patients reached the endpoint. The surveillance group had significantly lower incidence of the composite outcome (2.1% vs. 5.5%, adjusted odds ratio: 0.28, 95% confidential intervals: 0.09–0.94; p=0.039) and higher rates of prescriptions of cardioprotective drugs than the non-surveillance group. Conclusions: The incidence of cardiac complications was significantly lower in the surveillance group than the non-surveillance group, which supports the effectiveness of echocardiographic surveillance in patients with breast cancer. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Elsevier |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 識別子 |
|
|
識別子 |
https://doi.org/10.1016/j.jjcc.2023.07.002 |
|
識別子タイプ |
DOI |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0914-5087 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1876-4738 |
| 収録物名 |
|
|
収録物名 |
Journal of Cardiology |
|
言語 |
en |
| 書誌情報 |
巻 82,
号 6,
p. 467-472,
発行日 2023-12
|
K_No82p467.pdf (340 KB)
